Virax Biolabs Group Ltd., a biotechnology company listed on NASDAQ under the symbol "VRAX," has received a notification from The Nasdaq Stock Market LLC regarding a minimum bid price deficiency. According to a notice dated July 14, 2025, the company is not in compliance with NASDAQ Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Virax has until January 12, 2026, to regain compliance by achieving a closing bid price of at least $1.00 for a minimum of ten consecutive business days. The company may also be eligible for an additional 180-day grace period if compliance is not met by the deadline. Despite the notification, Virax's shares will continue to trade uninterrupted.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virax Biolabs Group Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA29637) on July 18, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.